Key Takeaway: Alberta Securities Commission British Columbia Securities Commission Ontario Securities Commission
RE: Xenon Pharmaceuticals Inc.
Pursuant to a request from the above-mentioned reporting issuer, we wish to advise you of the following information in connection with its Annual
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+56%
120-day peak, hindsight
Typical move
14.4%
average across 4 past catalysts
Cash runway
~39 mo
Minimal dilution risk
Lead asset
XPF-001
Phase 1 · Primary Erythromelalgia
Full Press Release Details
Alberta Securities Commission
British Columbia Securities Commission
Ontario Securities Commission
RE: Xenon Pharmaceuticals Inc.
Pursuant to a request from the above-mentioned reporting issuer, we wish to advise you of the following information in connection with its Annual Meeting of Shareholders:
Date of meeting:
June 1, 2017
Record date for notice:
April 4, 2017
Record date for voting:
April 4, 2017
Beneficial ownership determination date:
April 4, 2017
Securities entitled to notice:
Common Shares
Securities entitled to vote:
Common Shares
Issuer mailing directly to non objecting beneficial owners:
No
Issuer will pay for objecting beneficial owner material distribution:
Yes
Issuer using notice-and-access for registered investors:
No
Issuer using notice-and-access for non-registered investors: